BioCentury | Apr 13, 2021

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 12, 2021
Product Development

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

Agenus’ latest clinical data for AGEN1181 support the idea that Fc engineering can expand the population of patients who respond to checkpoint inhibitors.  While many companies are searching for the...
BioCentury | Apr 10, 2021
Product Development

Bispecific constructs move beyond T cell engagers at AACR

T cell engagers have dominated the bispecific antibody scene for the past five years, but the industry is starting to branch out into next-generation structures that offer new functions and potential improvements over first-generation compounds. ...
BioCentury | Apr 10, 2021
Product Development

MD Anderson AACR data in heavily pretreated lymphoma patients offer long-awaited lift to Affimed

Affimed has been working on NK cell engagers since before T cell engagers became popular but the latest data — which catapulted Affimed over the $1 billion market cap threshold — suggest the approach is...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

...factor TBRD4 - Bromodomain containing 4CD16a (FCGR3A; FcgammaRIIIa) - Fc gamma receptor IIIaCD16b (FcgammaRIIIb; FCGR3B) -Fc gamma receptor IIIb...
BioCentury | Feb 17, 2021

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

 Under a three-year deal, which builds on a 2020 agreement to develop therapies for coronaviruses, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) gained exclusive rights to collaborate with Vir Biotechnology Inc. (NASDAQ:VIR) on mAbs, including VIR-2482, to prevent or treat influenza....
BioCentury | Jan 9, 2021

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
BioCentury | Dec 17, 2020

GSK adds to next-generation checkpoint pipeline with Surface deal

GlaxoSmithKline’s $85 million deal with Surface Oncology caps off a big month for NK cell technologies and adds PVRIG to the growing list of NK cell checkpoint targets entering pharma pipelines. ...
BioCentury | Dec 9, 2020
Product Development

Dec. 8 COVID Quick Takes: U.K. Vaccines Taskforce to test combinations, plus advances from Clover, Lilly and India’s Serum Institute

U.K. plans to test vaccine combosThe U.K. Vaccines Taskforce will conduct a series of trials next year combining different COVID-19 vaccines, though it has not disclosed which vaccines will be included. Its year-end report stated that the availability...
BioCentury | Dec 8, 2020
Product Development

Dec. 7 ASH Quick Takes: CRISPR, Vertex update durability for edited cell therapy; plus J&J- Legend, Kura, Fate, Pfizer, Autolus and Affimed

Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) showed seven transfusion-dependent β thalassemia patients in the CLIMB-Thal-111 study remain transfusion-free for up to 18 months following CTX001...
Items per page:
1 - 10 of 188